NCT04227080View on ClinicalTrials.gov

BH4 Responsiveness in PAH Deficiency PKU Patients

PHASE4UnknownINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

June 30, 2022

Conditions

Pku PhenylketonuriaPAH Deficiency

Interventions

DRUG

BH4

oral administration of 20 mg/kg KUVAN (BH4)

Sponsors

Collaborators (1)

BioMarin Pharmaceutical

All Listed Sponsors

collaborator

BioMarin Pharmaceutical

INDUSTRY

lead

Taipei Veterans General Hospital, Taiwan

OTHER_GOV